These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35563245)

  • 1. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
    Horgan C; Jones SA; Bigger BW; Wynn R
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
    Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
    Mandolfo O; Liao A; Singh E; O'leary C; Holley RJ; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):243-255. PubMed ID: 37427450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II.
    Das S; Rruga F; Montepeloso A; Dimartino A; Spadini S; Corre G; Patel J; Cavalca E; Ferro F; Gatti A; Milazzo R; Galy A; Politi LS; Rizzardi GP; Vallanti G; Poletti V; Biffi A
    Mol Ther; 2024 Mar; 32(3):619-636. PubMed ID: 38310355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.
    Miwa S; Watabe AM; Shimada Y; Higuchi T; Kobayashi H; Fukuda T; Kato F; Ida H; Ohashi T
    Mol Genet Metab; 2020 Aug; 130(4):262-273. PubMed ID: 32631737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
    Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
    Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    Catalano F; Vlaar EC; Dammou Z; Katsavelis D; Huizer TF; Zundo G; Hoogeveen-Westerveld M; Oussoren E; van den Hout HJMP; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
    Hum Gene Ther; 2024 Apr; 35(7-8):256-268. PubMed ID: 38085235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and Gene Therapy in Hunter Disease.
    Sestito S; Falvo F; Scozzafava C; Apa R; Pensabene L; Bonapace G; Moricca MT; Concolino D
    Curr Gene Ther; 2018; 18(2):90-95. PubMed ID: 29618310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.